BSE filing, NSE: LLOYDSENGG. Summary written from the filing by ALFA Finder's alert engine.
Lloyds Engineering Works Ltd: key numbers
- Share price
- ₹83.11
- Market cap
- ₹12,893 Cr
- Revenue (annual)
- ₹1,301 Cr
- Net profit (annual)
- ₹189.9 Cr
- P/E (TTM)
- 57.9×Sector 50.0×
- Promoter holding
- 40.00%-1.91% QoQ
- FII holding
- 2.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lloyds Engineering Works Ltd
All →Lloyds Engineering Works Acquisition Worth ₹100 Cr
Lloyds Engineering Works approved acquisition of additional SISCOL shares for ₹100 Crore. The cash deal in tranches over 18 months strengthens its subsidiary holding.
- Value
- ₹100.0 Cr
- Execution
- 18 months
Lloyds Engineering Works Investor Presentation: Key Takeaways
Q2/H1 FY27 pro forma H1 total income ₹25,501 Mn (+74%), EBITDA ₹3,588 Mn (+50%), PAT ₹2,122 Mn (+33%). Order book ₹1,03,554 Mn.
Lloyds Engineering Works Other Announcement
Lloyds Engineering filed its quarterly Monitoring Agency Report for the rights issue. It confirms no deviation from the stated objects.
Lloyds Engineering Works Employee Stock Options
Lloyds Engineering allotted 2,55,697 equity shares under its ESOP 2021 at a Rs 9.50 exercise price. Vesting begins January 2027, and no exercise proceeds have been received yet.
Lloyds Engineering Works Capital Structure Change
Lloyds Engineering Works will invest Rs 100 Crore in subsidiary Steel Infra Solutions via preferential share subscription. Payment comes in two Rs 50 Crore tranches.
- Value
- ₹100.0 Cr
- Execution
- Whole transaction to complete within 18 months
Lloyds Engineering Works Q2 FY27 Results: Net Profit ₹57.8 Cr, Up 6.2% YoY
Lloyds Engineering Works Ltd reported revenue from operations of ₹593.5 Cr (+87.4% YoY) and net profit of ₹57.8 Cr (+6.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹57.8 Cr · +6.2% YoY
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.